VanEck Associates’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.08M | Buy |
196,524
+72,499
| +58% | +$2.61M | 0.01% | 593 |
|
|
2025
Q1 | $3.86M | Sell |
124,025
-3,115
| -2% | -$96.9K | 0.01% | 810 |
|
|
2024
Q4 | $3.24M | Buy |
127,140
+25,640
| +25% | +$654K | ﹤0.01% | 843 |
|
|
2024
Q3 | $2.78M | Buy |
101,500
+64,057
| +171% | +$1.75M | ﹤0.01% | 842 |
|
|
2024
Q2 | $988K | Buy |
37,443
+1,980
| +6% | +$52.2K | ﹤0.01% | 995 |
|
|
2024
Q1 | $1.08M | Buy |
35,463
+28,987
| +448% | +$880K | ﹤0.01% | 974 |
|
|
2023
Q4 | $182K | Buy |
6,476
+2,944
| +83% | +$82.7K | ﹤0.01% | 1176 |
|
|
2023
Q3 | $96K | Buy |
3,532
+309
| +10% | +$8.4K | ﹤0.01% | 1233 |
|
|
2023
Q2 | $99K | Buy |
+3,223
| New | +$99K | ﹤0.01% | 1244 |
|